Skip to content
Screener

Progyny PGNY Treasury Stock

Treasury Stock at other companies

CVS Health logo
CVS HealthCVS
$36.85B0.0%
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
$61.43M+191%
Biote Corp. logo
Biote Corp.BTMD
$14.83M+165%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$1.1B+47.5%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$43.5B-0.2%
Voya Financial logo
Voya FinancialVOYA
$1.35B+69.2%

Other financials

Income statement

See full
Revenue$350.5M+5.3%
Gross profit$89.3M+13.1%
Operating income$40.0M+64.2%
Net income$28.1M+63.9%
EPS (diluted)$0.34+78.9%

Balance sheet

See full
Cash & equivalents$152.6M+15.2%
Total debt$27.0M-5.8%
Total equity$453.3M-12.0%
Total assets$715.8M-5.9%

Cash flow

See full
Operating cash flow$50.4M-9.2%
CapEx$6.2M+18.0%
Free cash flow$44.2M-12.0%

Valuation

See full
Market cap$2.2B+17.7%
Enterprise value$2.08B+17.5%
P/E28×-7.2×
P/S1.7×+0.2×

Profitability

See full
Gross margin24.6%+2.2pp
Operating margin8.6%+2.4pp
Net margin6%+1.7pp
FCF margin13.6%-1.7pp

Returns & leverage

See full
Return on equity16.2%+5.3pp
Debt / equity0.1×0.0×
Current ratio2.1×-0.6×

Where this comes from

Reported directly by Progyny in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The source filing: Progyny’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 9:00 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001551306-26-000140
Line itemJune 30,2026December 31,2025
STOCKHOLDERS' EQUITY
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; at June 30, 2026 and December 31, 2025, respectively; 99,774,414 and 99,049,485 shares issued; 77,390,288 and 83,365,696 outstanding at June 30, 2026 and December 31, 2025, respectively99
Additional paid-in capital735,417700,785
Treasury stock, at cost, $0.0001 par value; 23,000,106 and 16,299,769 shares at June 30, 2026 and December 31, 2025, respectively(537,525)(388,075)
Accumulated earnings255,111202,827
Accumulated other comprehensive income245498
Total stockholders’ equity453,257516,044
Total liabilities and stockholders’ equity$715,836$742,435

Item 1. Financial Statements (Unaudited)

FAQ

What is Progyny's treasury stock?
Progyny (PGNY) reported treasury stock of $537.53M in Q2 2026.
How has Progyny's treasury stock changed year-over-year?
Progyny's treasury stock increased by 76.9% year-over-year, from $303.89M to $537.53M.
What is the long-term trend for Progyny's treasury stock?
Over 5 years (2020 to 2025), Progyny's treasury stock has grown at a 228.9% compound annual growth rate (CAGR), from $1.01M to $388.08M.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Ask your AI about Progyny's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude